platycodin d has been researched along with everolimus in 1 studies
| Studies (platycodin d) | Trials (platycodin d) | Recent Studies (post-2010) (platycodin d) | Studies (everolimus) | Trials (everolimus) | Recent Studies (post-2010) (everolimus) |
|---|---|---|---|---|---|
| 143 | 1 | 112 | 5,631 | 1,289 | 4,579 |
| Protein | Taxonomy | platycodin d (IC50) | everolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 2 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0022 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Dai, XY; Huang, ZJ; Jiang, HL; Li, T; Lu, JJ; Ouyang, DF; Wei, B; Weng, QJ; Yan, R; Zhu, H | 1 |
1 other study(ies) available for platycodin d and everolimus
| Article | Year |
|---|---|
Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Proliferation; Chaperonins; ErbB Receptors; Everolimus; HSP90 Heat-Shock Proteins; Humans; Immunosuppressive Agents; Lung Neoplasms; Oncogene Protein v-akt; Receptor, IGF Type 1; Receptors, Somatomedin; Saponins; TOR Serine-Threonine Kinases; Triterpenes | 2017 |